A 74-year-old female was diagnosed as having xanthinuria by measurement of the uric acid level in plasma, purine bases in urine and activity of xanthine oxidase in the duodenal mucosa. The determination of the urinary excretion of purine bases in her family demonstrated a slightly increased urinary excretion of oxypurines in her younger brother, suggesting that he was a heterozygote. The pyrazinamide-loading test and allopurinolloading test demonstrated that she could neither metabolize pyrazinoic acid into 5-hydroxypyrazinoic acid nor allopurinol into oxypurinol, although there was a slight metabolizing of prazinamide into 5-hydroxypyrazinamide. This suggested that she belonged to the subgroup which can neither metabolize pyrazinamide into 5-hydroxypyrazinamide, pyrazinoic acid into 5-hydroxypyrazinoic acid nor allopurinol into oxypurinol.
Xanthinuria is a disease in which the body congenitally lacks xanthine oxidase. The main symptoms of this disease are colicky pain due to xanthine stones in the urinary tract, accompanied by muscle pain and stiffness due to deposition of oxypurines.
Although xanthinuria had been thought to be unitary, we demonstrated in a previous study that this disease consists of two subgroups (1) . Having recently diagnosed a patient with hypertension and renal dysfunction as having xanthinuria, we tried to determine which subgroup this xanthinuric patient belonged.
SUBJECT AND METHODS
The patient was a 74-year-old female with a history of stones of the urinary tract. Her parents were consanguineous cousins. She had been treated during the past 2 yr for hypertension and renal dysfunction. Hypouricemia was discovered during an investigation of these diseases at the age of 71. On physical examination, she presented high blood pressure (210/108) and abdominal bruit but presented none of the neurological symptoms of sulfite oxidase deficiency.
The pyrazinamide loading test and allopurinol loading test were performed as follows. Three grams of pyrazinamide and 300 mg of allopurinol were administered orally in one dose at 1-month intervals.
In the study on the metabolism of pyrazinamide, urine was collected at 12-h intervals for 24 h and blood was drawn 4 h after the administration of pyrazinamide, while in the study on the metabolism of allopurinol, urine was collected for 12 h and blood was drawn 4 h after the administration of allopurinol. The urine samples obtained were stored at -20°C until assay. The plasma was promptly separated from the blood which had been taken by heparinized syringe, and was stored at -20°C until (3) . To exclude the effect of alcohol on purine bases in plasma and urine, urine samples were collected whenall subjects were on alcohol-free diets.
RESULTS
The patient's routine laboratory data are shown in Table 1 . Serum creatinine was 1.8 mg/dl and serum uric acid, 0.3 mg/dl. Other laboratory data were not remarkable. The patient's laboratory data on purine bases are shown in Table 2 . The concentrations of hypoxanthine and xanthine in plasma were markedly high in this patient, compared with normal values (Table 2 ). The urinary excretion of uric acid markedly decreased and, in contrast, that of hypoxanthine and xanthine markedly increased, compared with normal values (Table 2) . Fractional hypoxanthine clearance and fractional xanthine clearance increased despite the decreased creatinine clearance. The activity of xanthine oxidase of the duodenal mucosa was below the limits of detection, compared with 14.5 mmol/mg protein/h in a healthy control. Table 3 shows the urinary excretion of purine bases in the family including the proposita. The excretion of purine bases was within normal values except for the proposita and her younger brother. The increased urinary excretion of oxypurines and the decreased urinary excretion of uric acid were demonstrated in the proposita, while the slightly increased urinary excretion of oxypurines without the decreased urinary excretion of uric acid was demonstrated in her younger brother. The pedigree of the proposita is shown in Fig.  1 . Although xanthinuria was not detected by the measurement of oxypurines in urine except for the clearance; **fractional uric acid clearance (uric acid clearance/creatinine clearance x 100); ***fractional hypoxanthine clearance (hypoxanthine clearance/creatinine clearance X 100); ****i'ractional xanthine clearance (xanthine clearance/creatinine clearance X 100). 
DISCUSSION
Although the proposita was diagnosed as having xanthinuria by the measurement of xanthine oxidase activity and urinary oxypurines, it is known that a combined deficiency of sulfite oxidase, xanthine dehydrogenase and possibly aldehyde oxidase due to the absence of hepatic molybdenumco factor manifests similar biochemical characteristics to xanthinuria (4). However, this patient presented none of the neurological symptomsof patients with sulfite oxidase deficiency (convulsions, headache, coma, mental retardation and dislocation of the lenses), and also had normal urinary excretion of thiosulfate. Therefore, this patient did not suffer from a deficiency of sulfite oxidase. Although this patient's younger brother was suggested to be a heterozygote by the slightly increased urinary excretion of oxypurines, other family memberswere normal in regard to the urinary excretion of oxypurines.
The metabolism of pyrazinamide consists of two reaction sequences in humans (5-10) (Fig. 4) . One is the deamidation of pyrazinamide to pyrazinoic acid, followed by oxidation to 5-hydroxypyrazinoic acid by xanthine oxidase. The other is the direct oxidation of pyrazinamide to 5-hydroxypyrazinamide by xanthine oxidase. Previous studies demonstrated that pyrazinamide was not metabolized into 5-hydroxypyrazinoic acid via pyrazinoic acid but was metabolized into 5-hydroxypyrazinamide in a xanthinuric patient (7) and in a normal subject pretreated with allopurinol (10), and suggested that pyrazinamide was metabolized via an oxidative pathway other than that by xanthine oxidase. Allopurinol is oxidized to oxypurinol by xanthine oxidase in humans. Several studies demonstrated that allopurinol is not metabolized into oxypurinol in xanthinuric patients (1 1-15 ), while others demonstrated that it is metabolized into oxypurinol in xanthinuric patients (16) (17) (18) . These conflicting results suggest that allopurinol has an oxidative pathway by aldehyde oxidase and another by xanthine oxidase.
A previous study of the metabolism of pyrazinamide and allopurinol in xanthinuric patients suggested that xanthinuria is comprised at least two subgroups (1 The xanthinuria of the present patient seems to belong to the former subgroup rather than to the latter subgroup. This diagnosis was based on the fact that neither 5-hydroxypyrazinoic acid nor oxypurinol was excreted in urine in the pyrazinamide-loading test or allopurinolloading test, although small amounts (20 mg/day) of 5-hydroxypyrazinamide were excreted in urine in the pyrazinamide-loading test. The metabolism of both pyrazinamide and allopurinol has been studied in only three families with xanthinuria including the present case. Such a study needs to include other xanthinuric patients because the present case was different from the xanthinuria belonging to the former subgroup with respect to the urinary excretion of 5-hydroxypyrazinamide on the pyrazinamide-loading test. In addition, more studies on other xanthinuric patients are necessary to increase the data available based on the clinical findings for the two subgroups, and to facilitate reliable comparison of the two groups.
